| Medical and Health Sciences | 2021-2025 | 36 | US 18 | 99.99 |
| Biological Sciences | 2021-2025 | 392 | US 87 | 99.58 |
| Oncology | Lifetime | 225 | US 124 | 99.64 |
| Pulmonary and Respiratory Medicine | Lifetime | 330 | US 178 | 99.58 |
| Cancer Research | Lifetime | 342 | US 184 | 97.98 |
| Oncology | 2021-2025 | 4 | US 2 | 99.97 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 8 | US 3 | 99.97 |
| Cancer Research | 2021-2025 | 4 | US 1 | 99.87 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 129 | US 42 | 97.64 |
| Cancer Treatment and Pharmacology | Lifetime | 103 | US 57 | 99.64 |
| Advanced Breast Cancer Therapies | Lifetime | 38 | US 20 | 99.59 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 191 | US 113 | 99.51 |
| HER2/EGFR in Cancer Research | Lifetime | 101 | US 50 | 99.54 |
| Breast Cancer Treatment Studies | Lifetime | 148 | US 80 | 99.49 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 453 | US 263 | 99.18 |
| Cancer Genomics and Diagnostics | Lifetime | 752 | US 403 | 98.65 |
| Lung Cancer Research Studies | Lifetime | 471 | US 210 | 98.24 |
| Cancer-related Molecular Pathways | Lifetime | 798 | US 413 | 97.41 |
| PARP inhibition in cancer therapy | Lifetime | 268 | US 135 | 96.57 |
| Brain Metastases and Treatment | Lifetime | 511 | US 292 | 96.79 |
| Male Breast Health Studies | Lifetime | 343 | US 136 | 73.93 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 2 | US 1 | 99.91 |
| Breast Cancer Treatment Studies | 2021-2025 | 4 | US 2 | 99.97 |
| Cancer Genomics and Diagnostics | 2021-2025 | 10 | US 5 | 99.86 |
| Advanced Breast Cancer Therapies | 2021-2025 | 3 | US 3 | 99.95 |
| Cancer Treatment and Pharmacology | 2021-2025 | 5 | US 3 | 99.95 |
| HER2/EGFR in Cancer Research | 2021-2025 | 5 | US 3 | 99.95 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 47 | US 15 | 99.80 |
| Cancer-related Molecular Pathways | 2021-2025 | 5 | US 3 | 99.33 |
| Cancer Cells and Metastasis | 2021-2025 | 70 | US 17 | 96.66 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 112 | US 59 | 98.58 |
| Brain Metastases and Treatment | 2021-2025 | 73 | US 41 | 96.95 |
| Lung Cancer Research Studies | 2021-2025 | 241 | US 87 | 96.94 |
| Immunotherapy and Immune Responses | 2021-2025 | 484 | US 161 | 94.42 |
| PARP inhibition in cancer therapy | 2021-2025 | 212 | US 81 | 93.10 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 175 | US 72 | 87.25 |
| Breast Lesions and Carcinomas | 2021-2025 | 228 | US 73 | 89.63 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 743 | US 216 | 91.32 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 540 | US 134 | 90.59 |
| Estrogen and related hormone effects | 2021-2025 | 294 | US 111 | 85.27 |
| Male Breast Health Studies | 2021-2025 | 26 | US 13 | 83.63 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 500 | US 101 | 75.69 |
